Quest Diagnostics
OverviewSuggest Edit
Quest Diagnostics is a company providing diagnostic testing, information, and services. It offers diagnostic testing services through its network of laboratories and patient service centers, interpretive consultation through its medical and scientific staff, cancer diagnostics, and anatomic pathology services. The company serves patients, healthcare providers, pharmaceutical medical device companies, life insurance companies, and employers.
| Type | Public | |
| Founded | 1967 | |
| HQ | Secaucus, US | Map |
| Website | questdiagnostics.com | |
| Employee Ratings | More | |
| Overall Culture | C+ | More |
Recent NewsAll News
- Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond
- Global Autoimmune Diseases Diagnostics Market Report 2020-2025 with Profiles of Abbott Laboratories, Siemens AG, Beckman Coulter Inc. and Quest Diagnostics
- Quest Diagnostics shares jump 3.8% premarket as earnings beat on demand for COVID-19 tests
- Fentanyl and Heroin Misuse Skyrockets During COVID-19 Pandemic, Finds Quest Diagnostics Health Trends Study
Key People/Management at Quest Diagnostics
Tim Sharpe
Vice President, Compliance
Shawn Bevec
Vice President, Investor Relations
Stephen H. Rusckowski
Chairman, CEO and President
Mark J. Guinan
Executive Vice President and Chief Financial Officer
Cecilia McKenney
Senior Vice President, Chief Human Resources Officer
Manuel O. Méndez
Senior Vice President and Chief Commercial Officer
Quest Diagnostics Office Locations
Quest Diagnostics has offices in Secaucus, Santana De Parnaiba, Dublin and Ciudad de México
Secaucus, US (HQ)
500 Plaza Dr
Santana De Parnaiba, BR
1818 Estrada Tenente Marques, A06 & A07
Dublin, IE
Block 1, Unit 10, 9 Northwood Ave, Northside
Ciudad de México, MX
Frontera 4, Roma Nte., Cuauhtémoc
Ciudad de México, MX
World Trade Center 9th Floor, Office 19 Col. Napoles, Deleg. Benito Juarez
Quest Diagnostics Financials and Metrics
Quest Diagnostics Revenue
Quest Diagnostics's revenue was reported to be $7.73 b in FY, 2019
| USD | |
|---|---|
Revenue (Q3, 2020) | 2.8b |
Gross profit (Q3, 2020) | 1.2b |
Gross profit margin (Q3, 2020), % | 43.3% |
Net income (Q3, 2020) | 591.0m |
EBIT (Q3, 2020) | 718.0m |
Market capitalization (12-Nov-2020) | 16.4b |
Closing stock price (12-Nov-2020) | 121.4 |
Cash (30-Sept-2020) | 1.6b |
EV | 19.9b |
Quest Diagnostics's current market capitalization is $16.4 b.
Annual
Quarterly
| USD | Q1, 2010 | Q2, 2010 | Q3, 2010 | Q4, 2010 | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q4, 2011 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.8b | 1.9b | 1.9b | 7.4b | 1.8b | 1.9b | 1.9b | 7.5b | 1.9b | 1.9b | 1.8b | 1.8b | 1.8b | 1.7b | 1.9b | 1.9b | 1.8b | 1.9b | 1.9b | 1.9b | 1.9b | 1.9b | 1.9b | 1.9b | 1.9b | 1.9b | 3.8b | 1.9b | 1.9b | 2.0b | 2.0b | 1.8b | 1.8b | 2.8b |
Cost of goods sold | 1.1b | 1.1b | 1.1b | 4.3b | 1.1b | 1.1b | 1.1b | 4.4b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.2b | 1.2b | 1.2b | 1.2b | 1.1b | 1.2b | 1.2b | 1.2b | 1.2b | 1.2b | 1.2b | 2.5b | 1.2b | 1.2b | 1.3b | 1.3b | 1.3b | 1.2b | 1.6b |
Gross profit | 739.1m | 795.8m | 773.2m | 3.1b | 724.6m | 798.8m | 789.8m | 3.1b | 796.3m | 761.7m | 694.8m | 722.1m | 698.6m | 645.0m | 728.0m | 726.0m | 676.0m | 743.0m | 718.0m | 719.0m | 751.0m | 728.0m | 734.0m | 773.0m | 741.0m | 658.0m | 1.3b | 667.0m | 647.0m | 688.0m | 692.0m | 552.0m | 606.0m | 1.2b |
Gross profit Margin, % | 41% | 42% | 41% | 41% | 40% | 42% | 41% | 41% | 42% | 41% | 39% | 40% | 39% | 37% | 38% | 38% | 37% | 39% | 38% | 39% | 39% | 39% | 39% | 40% | 38% | 35% | 35% | 35% | 34% | 35% | 35% | 30% | 33% | 43% |
Annual
Quarterly
| USD | Q1, 2010 | Q2, 2010 | Q3, 2010 | Q4, 2010 | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q4, 2011 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 463.2m | 447.9m | 369.3m | 449.3m | 994.2m | 184.2m | 110.8m | 164.9m | 173.7m | 191.8m | 133.6m | 148.3m | 158.3m | 144.0m | 144.0m | 170.0m | 974.0m | 150.0m | 123.0m | 128.0m | 283.0m | 406.0m | 367.0m | 314.0m | 350.0m | 124.0m | 132.0m | 263.0m | 464.0m | 273.0m | 434.0m | 342.0m | 988.0m | 1.6b |
Accounts Receivable | 865.2m | 869.6m | 884.1m | 845.3m | 940.4m | 929.4m | 936.3m | 906.5m | 941.5m | 930.7m | 930.0m | 946.8m | 1.1b | 1.1b | 1.1b | 1.1b | 972.0m | 1.1b | 1.4b | |||||||||||||||
Prepaid Expenses | 313.8m | 299.4m | 310.8m | 365.4m | 364.4m | 349.2m | 329.9m | 108.4m | 86.2m | 97.8m | 126.4m | 148.0m | 137.0m | 100.0m | 116.0m | 120.0m | 112.0m | 117.0m | ||||||||||||||||
Inventories | 79.5m | 78.4m | 73.2m | 76.6m | 71.7m | 88.0m | 85.0m | 89.1m | 90.1m | 94.5m | 89.8m | 89.4m | 85.2m | 99.0m | 109.0m | 111.0m | 106.0m | 109.0m | 86.0m | 82.0m | 80.0m | 82.0m | 77.0m | 83.0m | 100.0m | 94.0m | 91.0m | 95.0m | 98.0m | 105.0m | 112.0m | 126.0m | 154.0m | 205.0m |
Annual
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|
Net Income | 555.7m | 883.0m | 592.0m | 753.0m | 696.0m | 824.0m | 788.0m | 906.0m |
Depreciation and Amortization | 286.6m | 304.0m | 249.0m | 270.0m | 309.0m | 329.0m | ||
Accounts Payable | (13.2m) | (21.0m) | 68.0m | (24.0m) | 56.0m | (8.0m) | (19.0m) | 73.0m |
Cash From Operating Activities | 1.2b | 652.0m | 938.0m | 821.0m | 1.1b | 1.2b | 1.2b | 1.2b |
Quarterly
| USD | Q1, 2010 | Q2, 2010 | Q3, 2010 | Q4, 2010 | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q4, 2011 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 171.2m | 357.1m | 555.1m | 720.9m | (53.9m) | 109.3m | 281.1m | 470.6m | 336.8m | 499.9m | 135.8m | 301.2m | 732.1m | 111.0m | 253.0m | 392.0m | 70.0m | 199.0m | 553.0m | 114.0m | 324.0m | 529.0m | 175.0m | 382.0m | 557.0m | 189.0m | 422.0m | 649.0m | 164.0m | 415.0m | 641.0m | 106.0m | 299.0m | 890.0m |
Depreciation and Amortization | 63.3m | 126.3m | 190.4m | 254.0m | 63.4m | 136.1m | 209.4m | 281.1m | 144.0m | 215.3m | 70.2m | 142.0m | 211.0m | 75.0m | 156.0m | 235.0m | 78.0m | 153.0m | 230.0m | 62.0m | 123.0m | 186.0m | 62.0m | 128.0m | 197.0m | 74.0m | 151.0m | 228.0m | 108.0m | 165.0m | 247.0m | 85.0m | 174.0m | 263.0m |
Accounts Payable | (81.9m) | (84.6m) | (26.6m) | 18.2m | (47.1m) | (74.5m) | (84.4m) | (17.6m) | (87.7m) | (56.1m) | (77.1m) | (68.2m) | (76.8m) | (86.0m) | (39.0m) | 20.0m | (120.0m) | (49.0m) | (41.0m) | (77.0m) | 23.0m | 43.0m | (95.0m) | (93.0m) | (3.0m) | (68.0m) | (64.0m) | 51.0m | 32.0m | 27.0m | 80.0m | (47.0m) | 42.0m | 514.0m |
Cash From Operating Activities | 239.2m | 448.4m | 778.5m | 1.1b | 160.6m | 220.1m | 557.7m | 895.5m | 412.1m | 806.8m | 47.2m | 255.3m | 441.6m | 84.0m | 364.0m | 635.0m | 52.0m | 327.0m | 539.0m | 143.0m | 464.0m | 765.0m | 196.0m | 490.0m | 852.0m | 180.0m | 503.0m | 905.0m | 275.0m | 596.0m | 895.0m | 247.0m | 602.0m | 1.5b |
| USD | Q1, 2010 |
|---|---|
Financial Leverage | 2.2 x |
Quest Diagnostics Operating Metrics
| FY, 2016 | |
|---|---|
Accounts | 250 k |
Patents Issued | 700 |
Patents Pending | 570 |
Patient Service Centers | 2.20 k |
Quest Diagnostics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| California Laboratory Associates | October 30, 2017 | |
| Cleveland HeartLab | October 18, 2017 | |
| Cape Cod Healthcare - Business | June 28, 2017 | |
| ClearPoint Diagnostic | June 12, 2017 | |
| Med fusion | June 12, 2017 | |
| PeaceHealth Laboratories | February 15, 2017 |
Quest Diagnostics Revenue Breakdown
Quest Diagnostics revenue breakdown by business segment: 95.6% from Diagnostic Information Services and 4.4% from Other
Quest Diagnostics Cybersecurity Score
Quest Diagnostics Environment, Social & Governance (ESG) Ratings
Quest Diagnostics Online and Social Media Presence
11.31k Twitter followers
Quest Diagnostics has 11.31k Twitter Followers. The number of followers has increased 0.4% month over month and increased 2.6% quarter over quarter
Quest Diagnostics's Trends
Twitter Engagement Stats for @QuestDX
9.6k
Tweets
600
Following
11.3k
Followers
80
Tweets last 30 days
0.9
Avg. likes per Tweet
25%
Tweets with engagement
Quest Diagnostics Company Culture
Overall Culture
C+
65/100
CEO Rating
C+
67/100
Compensation
C+
64/100
Diversity
B
71/100
Quest Diagnostics News and Updates
October 27, 2020
Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond
SECAUCUS, N.J., Oct. 27, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help...
October 26, 2020
Global Autoimmune Diseases Diagnostics Market Report 2020-2025 with Profiles of Abbott Laboratories, Siemens AG, Beckman Coulter Inc. and Quest Diagnostics
Dublin, Oct. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Autoimmune Diseases Diagnostics Market 2020-2025 by Product, Test Type, Disease, End-user, Geography and Impact of Covid-19 with Ansoff's Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Autoimmune Disease Diag…
October 22, 2020
Quest Diagnostics shares jump 3.8% premarket as earnings beat on demand for COVID-19 tests
Quest Diagnostics Inc. shares jumped 3.8% in premarket trade Thursday, after the company beat third-quarter earnings estimates and raised guidance, buoyed by demand for COVID-19 testing. Secaucus, N.J.-based Quest said it had net income of $568 million, or $4.14 a share, in the quarter, up from $21…
October 15, 2020
Fentanyl and Heroin Misuse Skyrockets During COVID-19 Pandemic, Finds Quest Diagnostics Health Trends Study
SECAUCUS, N.J., Oct. 15, 2020 /PRNewswire/ -- A new Quest Diagnostics Health Trends study indicates that misuse of fentanyl, heroin and nonprescribed opioids are on the rise, potentially due to the COVID-19 pandemic's impact on healthcare access and support for individuals most at-risk...
October 15, 2020
National Business Group on Health Honors Quest Diagnostics with Best Employers: Excellence in Health & Well-Being Award
SECAUCUS, N.J., Oct. 15, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received the 2020 Best Employers: Excellence in Health & Well-Being award, presented by the National Business Group on...
October 14, 2020
Quest Diagnostics Receives 2020 C. Everett Koop National Health Award for Outstanding Employee Health Program
SECAUCUS, N.J., Oct. 12, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received the prestigious C. Everett Koop National Health Award for 2020. Named for C. Everett Koop, the 13th Surgeon...
Quest Diagnostics Blogs
November 16, 2020
Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma
Collaboration will include COVID-19 IgG antibody testing for up to 1,000 study participants
October 22, 2020
Quest Diagnostics Reports Third Quarter 2020 Financial Results, Reflecting Continued Demand for COVID-19 Testing and Rapid Recovery in Health Care Utilization
- Third quarter revenues of $2.79 billion, up 42.5% from 2019
October 13, 2020
Walmart, Quest Diagnostics and DroneUp Pilot COVID-19 AT-Home Self-Collection Kit Delivery in Cheektowaga, New York
Qualified residents in close proximity to Cheektowaga Walmart may be able to receive
at-home self-collection kits by drone delivery
October 05, 2020
CLEAR and Quest Diagnostics Collaborate to Integrate COVID-19 Test Results with "Health Pass" for Safer Environments
Nationwide Collaboration Creates Multi-Layered Approach to Public Health Safety
Quest Diagnostics Frequently Asked Questions
When was Quest Diagnostics founded?
Quest Diagnostics was founded in 1967.
Who are Quest Diagnostics key executives?
Quest Diagnostics's key executives are Tim Sharpe, Shawn Bevec and Stephen H. Rusckowski.
How many employees does Quest Diagnostics have?
Quest Diagnostics has 47,000 employees.
What is Quest Diagnostics revenue?
Latest Quest Diagnostics annual revenue is $7.7 b.
What is Quest Diagnostics revenue per employee?
Latest Quest Diagnostics revenue per employee is $164.4 k.
Who are Quest Diagnostics competitors?
Competitors of Quest Diagnostics include Invitae, Sonic Healthcare and Abbott.
Where is Quest Diagnostics headquarters?
Quest Diagnostics headquarters is located at 500 Plaza Dr, Secaucus.
Where are Quest Diagnostics offices?
Quest Diagnostics has offices in Secaucus, Santana De Parnaiba, Dublin and Ciudad de México.
How many offices does Quest Diagnostics have?
Quest Diagnostics has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies